Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | IDH1 | O75874 | 5/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266818 | 1.00 | GLS (0.46) | GLSLMNAADORA3IDH1SCD5 | |
| SCHEMBL12333636 | 1.00 | GLS (0.46) | GLSLMNAADORA3IDH1SCD5 | |
| SCHEMBL14665075 | 0.87 | GLS (0.44) | GLSLMNAIDH1SCD5NPC1 | |
| SCHEMBL14665079 | 0.87 | GLS (0.44) | GLSLMNAIDH1SCD5NPC1 | |
| SCHEMBL8138150 | 0.83 | HDAC1 (0.44) | GLSLMNAIDH1SCD5NPC1 | |
| SCHEMBL6948748 | 0.83 | GLS (0.42) | GLSLMNAIDH1SCD5NPC1 | |
| SCHEMBL14665118 | 0.83 | GLS (0.49) | GLSLMNASCD5NPC1TP53 | |
| SCHEMBL14665137 | 0.83 | GLS (0.49) | GLSLMNASCD5NPC1TP53 | |
| SCHEMBL6433693 | 0.83 | POLB (0.42) | GLSSCD5NPSR1 | |
| SCHEMBL15743835 | 0.83 | GLS (0.49) | GLSLMNASCD5NPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478438-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20220127233-A1 | SUBSTITUTED QUINOLINYLCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | BRISTOL MYERS SQUIBB CO (US) | 2022-04-28 | — | — | US | disclosed |
| US-11236048-B2 | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-01 | — | — | US | disclosed |
| CN-107108492-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2021-03-19 | — | — | CN | disclosed |
| US-20200182617-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200123109-A1 | SUBSTITUTED QUINOLINYLCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | BRISTOL-MYERS SQUIBB COMPANY | 2020-04-23 | — | — | US | disclosed |
| US-10555920-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-11 | — | — | US | disclosed |
| US-20190038578-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-02-07 | — | — | US | disclosed |
| US-10092529-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-10-09 | — | — | US | disclosed |
| EP-3224245-B1 | NECROSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2018-09-12 | — | — | EP | disclosed |
| US-20170304237-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-26 | — | — | US | disclosed |
| EP-3224245-A1 | NECROSIS INHIBITORS | National Institute Of Biological Sciences, Beijing (CN) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016101887-A1 | NECROSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304237-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | GLS 1766/4885LMNA 2712/4885ADORA3 4190/4885 |
| US-11478438-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | GLS 2215/4885LMNA 2442/4885ADORA3 3598/4885 |
| US-11236048-B2 | Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation | QARS1, BCHE, NQO2 | GLS 188/4885LMNA 482/4885ADORA3 2301/4885 |
| US-20190038578-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | GLS 2215/4885LMNA 2442/4885ADORA3 3598/4885 |
| US-20200123109-A1 | SUBSTITUTED QUINOLINYLCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | QARS1, BCHE, NQO2 | GLS 188/4885LMNA 482/4885ADORA3 2301/4885 |
| US-10092529-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | GLS 1766/4885LMNA 2712/4885ADORA3 4190/4885 |
| US-10555920-B2 | Necrosis inhibitors | RIPK3, RIPK1, RIPK4 | GLS 2215/4885LMNA 2442/4885ADORA3 3598/4885 |
| US-20220127233-A1 | SUBSTITUTED QUINOLINYLCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION | QARS1, BCHE, NQO2 | GLS 188/4885LMNA 482/4885ADORA3 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.